The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce additional doses of its investigational Ebola vaccine over the next year as part of the international response to the outbreak in the Democratic Republic of the Congo, and for domestic biodefense preparedness. Health officials in the DRC have vaccinated more than 192,000 high-risk contacts of infected people with the investigational vaccine, which has shown effectiveness against Ebola. ASPR’s Biomedical Advanced Research and Development Authority continues to work with Merck to advance development of the vaccine for licensure by the Food and Drug Administration. 
 

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday joined the World Health Organization to declare the end of the Ebola Virus Disease outbreak in the…
Headline
The Food and Drug Administration yesterday approved the first FDA-approved vaccine to prevent Ebola in adults with Zaire ebolavirus, which killed more…
Headline
The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living…
Headline
The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which…
Headline
The World Health Organization recently deployed a rapid response team and personal protective equipment to the United Republic of Tanzania following unofficial…
Headline
Patients receiving either of two investigational treatments for Ebola in the Democratic Republic of the Congo had a greater chance of survival than those…